Clin Pediatr Hematol Oncol.  2015 Oct;22(2):161-166. 10.15264/cpho.2015.22.2.161.

A Case of Kasabach-Merritt Syndrome Successfully Treated with Interferon-alpha 2b and Propranolol

• Lee JW
• Jung HL
• Shim JW
• Kim DS
• Shim JY
• Park MS
• Park HJ

• KMID: 2084618
• DOI: http://doi.org/10.15264/cpho.2015.22.2.161

Abstract

Kasabach-Merritt syndrome (KMS) is a rare, life-threatening disease characterized by rapidly enlarging hemangioma and consumptive coagulopathy. We report a case of KMS in a 28-day-old female neonate with a huge mixed type hemangioma on her right thigh with muscle involvement and severe venous engorgement, who was refractory to prednisone therapy, but was successfully managed with the interferon (IFN)-alpha 2b and propranolol combination therapy. By the third week of IFN-alpha 2b treatment, hematological parameters had normalized and the hemangioma size had dramatically decreased, and after 5 months of the treatment, complete resolution was observed visually. We also measured serum levels of cytokines including vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), monocyte chemoattractant protein-1 (MCP-1) and platelet-derived growth factor-BB (PDGF-BB), at diagnosis and serially during treatment but the levels did not correlate with the clinical response. The patient has not shown relapse after 20 months of follow up.

Keyword

Kasabach-Merritt syndrome; Hemangioma; Cytokine; Interferon

MeSH Terms

Chemokine CCL2
Cytokines
Diagnosis
Female
Fibroblast Growth Factor 2
Follow-Up Studies
Hemangioma
Humans
Hyperemia
Infant, Newborn
Interferon-alpha*
Interferons
Kasabach-Merritt Syndrome*
Prednisone
Propranolol*
Recurrence
Thigh
Vascular Endothelial Growth Factor A
Chemokine CCL2
Cytokines
Fibroblast Growth Factor 2
Interferon-alpha
Interferons
Prednisone
Propranolol
Vascular Endothelial Growth Factor A